Case studies
Impact of Accelerator™ Drug Development:
One partner, real results
In drug development and clinical research, relying on disconnected providers often leads to knowledge and service gaps, causing significant delays and missed opportunities.
Thermo Fisher Scientific’s Accelerator™ Drug Development streamlines your entire journey by integrating a full suite of CDMO and CRO services as core offerings and supporting you in each phase – from preclinical to commercial – across all major drug modalities and therapeutic areas.
We help developers of all sizes navigate complexity, meet milestones efficiently, and reduce interruptions, with an approach that eliminates timeline gaps and mitigates risk.
These case studies showcase how our fully integrated, end-to-end approach has made a measurable difference for organizations like yours.
When API and study design complications threatened progress, integrated preclinical solutions within the Accelerator™ Drug Development framework helped to reduce risk and drive efficiency.
Discover how Accelerator™ Drug Development enabled the fragmented internal team of a global biopharma sponsor to manage multiple parallel studies – and meet enrollment goals.
See how integration and foresight helped identify and resolve potential bottlenecks before they affected an FPI milestone, turning a high-risk timeline into repeatable success.